申请人:Boehringer Ingelheim International GmbH
公开号:US11136336B2
公开(公告)日:2021-10-05
This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
本发明涉及噻吩嘧啶酮及其作为 TRPA1 活性抑制剂的用途、含有噻吩嘧啶酮的药物组合物,以及使用噻吩嘧啶酮作为治疗和/或预防纤维化疾病、炎症性和自身免疫性疾病以及中枢神经系统相关疾病的药物的方法。